arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Perspective Therapeutics, Inc.

CATX
$0.79 ▼ -0.09 (-10.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
64 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
53
Health
Fair
Neutral
auto_awesome

Analytical Summary

Perspective Therapeutics, Inc. demonstrates solid fundamentals with strength in Debt to Equity. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $95.3M
Dividend Yield —
Revenue Growth None
Op. Margin None
ROIC -7.1% ↘
FCF / Share $-0.29 ↗
Trailing P/E —
Price / Book 0.3x
FCF Yield —
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Nov 5, 2026.

64-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.19M
↑ +27.3% —
Net Income Profit after all expenses
$-26.19M
↓ -44.1% —
Operating Margin Operating profit as % of sales
-482.1%
↓ -96.7% —
FCF / Share Free cash flow per share
$-0.29
↑ +21.9% —
Long-Term Debt Long-term obligations
$1.60M
↓ -0.8% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
17
Financial Health ↓
94
Cash Quality ↓
62

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 16 years · 64 quarters